Nalox-1 Pharmaceuticals LLC

Company overview. Nalox-1 Pharmaceuticals, LLC is a Delaware limited liability company used as a patent-challenge vehicle. It is 100% owned by BCIM Partners III, LP, a Delaware limited partnership whose investment manager is Burford Capital Investment Management LLC. In its PTAB filings Nalox-1 identified itself plus BCIM Partners III, LP, BCIM General Partner III, LP, BCIM PIII Holdings, LLC, Burford Capital Ireland DAC, Burford Capital Investment Management LLC, Burford Capital Holdings (UK) Limited, and Burford Capital Limited as real parties in interest, and stated the petition costs were expected to be borne by those entities. No employee count, revenue, or market capitalization is reported for the LLC; Burford Capital Limited is the publicly listed parent (LSE/NYSE: BUR), a litigation-finance firm.

Products / services / operations. Nalox-1 is a non-practicing entity with no products, manufacturing, or commercial operations. It does not assert a patent portfolio of its own; its assets are litigation positions funded by Burford-affiliated capital. Emergent BioSolutions' securities filings describe Nalox-1 as "a non-practicing entity." Its activity targeted the Orange Book–listed patents covering NARCAN (naloxone HCl) Nasal Spray 4 mg — a needle-free opioid-overdose reversal product developed by Opiant Pharmaceuticals and marketed by Adapt Pharma Operations Limited (an Emergent BioSolutions subsidiary).

Patent-litigation posture. All four tracked matters are petitions for inter partes review filed at the PTAB on February 19, 2019, with Nalox-1 as petitioner (shown as plaintiff) and Adapt Pharma / Opiant as patent owners; it has never been a defendant. Nalox-1 filed fifteen IPR petitions covering five Narcan patents (U.S. 9,211,253; 9,468,747; 9,561,177; 9,629,965; 9,775,838). The Board instituted review of the '253, '747, and '965 patents and denied the rest as redundant. No district-court suits and no Eastern District of Texas activity are attributed to Nalox-1; the parallel district litigation was brought by Adapt/Opiant against Teva (D.N.J.).

Notable cases / context. The tracked cases — Nalox-1 v. Opiant Pharmaceuticals and Nalox-1 v. Adapt Pharma — ran parallel to Adapt/Opiant v. Teva, where the New Jersey court held certain claims of the '747, '177, '965, and '838 patents invalid in June 2020. The PTAB's August 2020 final decisions in the instituted proceedings declined to hold the '747 and '965 claims unpatentable, creating an acknowledged conflict with the district court on the same prior art.